Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation.

Abstract

Intravenous cyclophosphamide remains an important therapy for patients with severe systemic lupus erythematosus--including lupus nephritis, which primarily affects women in their reproductive years. As prognosis improves, the chronic toxicity of this therapy assumes greater importance. This article reviews cyclophosphamide use, its effect on gonadal function, and protection of gonadal reserve during therapy. Egg, embryo, or gonadal tissue cryopreservation and alternative therapeutic strategies are considered.

• Authors: Jennifer Mersereau, Mary Anne Dooley
• Journal: Rheumatic diseases clinics of North America (Rheum Dis Clin North Am) Vol. 36 Issue 1 Pg. 99-108, viii (Feb 2010) ISSN: 1558-3163 [Electronic] United States
• PMID: 20202593 (Publication Type: Journal Article)
• Copyright: Copyright 2010 Elsevier Inc. All rights reserved.

Chemical References

• Immunosuppressive Agents
• Gonadotropin-Releasing Hormone
• Cyclophosphamide

Topics

• Adult
• Animals
• Cyclophosphamide (administration & dosage, adverse effects)
• Female
• Gonadotropin-Releasing Hormone (agonists)
• Humans
• Immunosuppressive Agents (administration & dosage, adverse effects)
• Infertility, Female (chemically induced, prevention & control)
• Infertility, Male (chemically induced, prevention & control)
• Infusions, Intravenous
• Lupus Nephritis (drug therapy)
• Male
• Ovary (drug effects)
• Primary Ovarian Insufficiency (chemically induced, prevention & control)
• Rats
• Reproductive Techniques, Assisted
• Spermatozoa (drug effects)
• Young Adult